The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide

Launched by AMERICAN UNIVERSITY OF BEIRUT MEDICAL CENTER · Jul 26, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how different diets affect the stiffness of blood vessels in people who are starting a medication called Semaglutide to help with weight loss. Specifically, the researchers want to compare the Mediterranean diet, which is rich in fruits, vegetables, and healthy fats, with a high protein and low carbohydrate diet. They will measure changes in blood vessel stiffness and other health indicators over a six-month period to see which diet may be more effective for people with obesity.

To participate in the trial, you need to be a man or a premenopausal woman aged 18 to 49 with a body mass index (BMI) of 30 or higher, and you should be starting Semaglutide for weight management. You must be able to attend scheduled visits over the six months of the study. However, certain individuals, such as those who are pregnant, have uncontrolled health conditions, or have had specific weight loss surgeries, are not eligible to join. If you choose to participate, you can expect regular check-ins to monitor your health as you follow one of the diets.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and premenopausal women, 18-49 years, with obesity defined as BMI ≥ 30 kg/m2
• • Upon the initiation of Semaglutide (within the first 1-4 weeks) for medical weight management, for clinical purposes, as advised by the primary physician
• • Able to commit for a 6-month trial visits
• Exclusion Criteria:
• • Pregnant women
• • Patients who are taking or have taken other weight reducing drug therapies in the previous 6 months
• • Patients who have undergone metabolic weight loss surgery
• • Patients known to have diabetes (HbA1c ≥6.5% at screening)
• • Patients with uncontrolled hypertension
• • Patients with uncontrolled cardiac disease, pulmonary, renal or liver diseases, active cancer or psychiatric diseases
• • Patients with excessive alcohol intake, defined as ≥ 2 glasses per day
• • Patients known to have uncontrolled/ untreated thyroid disorders.
• • Patients with cushing disease or polycystic ovaries, and those with neuro-endocrine or drug induced obesity (such as anti-psychotic, steroids, hormonal therapy): Such patients are resistant to weight loss, and they need treatment of their primary disease and/or cessation of the culprit medication to lose weight
• • Patients with untreated gout
• • Patients who have undergone bariatric surgery